E-LEK: Independent Drug & Healthcare Newsletter for October 2016
------------------------------------------------------------
---------------------------------
Newsletter, October 2016
If your friends or colleagues would be interested, forward this email and
invite them to sign up for the free Newsletter.
N° 175 October 2016
View the table of contents for the current issue
Subscribe to Prescrire International
In Prescrire's Spotlight this month
Metoclopramide, domperidone: sudden cardiac death, ventricular arrhythmia
FEATURED REVIEW The neuroleptics metoclopramide and domperidone have been
used since the 1960s and the 1980s respectively for nausea and vomiting.
Their limited efficacy and the severity of their adverse effects have
slowly come to light over time. Results published in 2015 confirmed and
quantified the risks of serious arrhythmia and sudden cardiac death with
both drugs.
Read more
In the October issue of Prescrire International:
Prucalopride (Resolor°) and chronic constipation in men
FREE DOWNLOAD
For men presenting with constipation, a troublesome but usually benign
disorder, prucalopride carries a disproportionate risk of cardiovascular
disorders, depression and suicidal ideation. As in women, it is better to
optimise the use of standard laxatives, and to avoid prucalopride
altogether.
Read more
Caring for vulnerable migrants.
A discussion-debate (in French) organised by Prescrire in Paris on 6
October 2016
Migrants, refugees: women, children and men are often in a situation of
extreme vulnerability. How can they be provided with the healthcare they
need, on both an emergency and a longer-term basis?
A discussion-debate in French on this important topic will be organised by
Prescrire in Paris on 6 October.
Read more
Falls in the elderly: proven benefits of exercise
Following on from others, a new trial has shown the benefits of exercise in
preventing falls with trauma in elderly women.
Read more
MedDRA and pharmacovigilance: a complex and little-evaluated tool
The standardised "Medical Dictionary for Regulatory Activities" (MedDRA) is
used for coding adverse effects in clinical study reports and
pharmacovigilance databases. Its complexity and its poorly evaluated
performance make it susceptible to manipulation, errors of interpretation
and bias.
Read more
Share this with a friend or colleague: Forward this email
Get this from a friend?
Sign up here
Prescrire International <international@prescrire.org>